AMNEAL PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Noncontrolling Interest
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Net Income (Loss) Attributable to Noncontrolling Interest of $11.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was $11.95M, a 9.41% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was $15.74M, a 26.73% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was $14.50M, a 40.22% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was $15.76M, a 32.32% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2025 was $55.88M, a 29.91% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2024 was $43.01M, a 21.94% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2023 was $35.27M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2022 was -$125.24M, a 1411.97% decline from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.95M 10-Q · filed 2026-08-06 | $27.70M 10-Q · filed 2026-08-06 | $42.19M derived: sum of 3 quarters · filed 2026-08-06 | $57.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.74M 10-Q · filed 2026-05-07 | $30.24M derived: sum of 2 quarters · filed 2026-05-07 | $46.00M derived: sum of 3 quarters · filed 2026-05-07 | $59.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $14.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $30.26M derived: sum of 2 quarters · filed 2026-02-27 | $43.45M derived: sum of 3 quarters · filed 2026-08-06 | $55.88M 10-K · filed 2026-02-27 |
| 2025-09-30 | $15.76M 10-Q · filed 2025-11-06 | $28.96M derived: sum of 2 quarters · filed 2026-08-06 | $41.38M 10-Q · filed 2025-11-06 | $51.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $13.19M 10-Q · filed 2026-08-06 | $25.62M 10-Q · filed 2026-08-06 | $35.95M derived: sum of 3 quarters · filed 2026-08-06 | $47.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $12.42M 10-Q · filed 2026-05-07 | $22.76M derived: sum of 2 quarters · filed 2026-05-07 | $34.67M derived: sum of 3 quarters · filed 2026-05-07 | $45.47M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $22.25M derived: sum of 2 quarters · filed 2026-02-27 | $33.05M derived: sum of 3 quarters · filed 2026-02-27 | $43.01M 10-K · filed 2026-02-27 |
| 2024-09-30 | $11.91M 10-Q · filed 2025-11-06 | $22.71M derived: sum of 2 quarters · filed 2025-11-06 | $32.67M 10-Q · filed 2025-11-06 | $37.98M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $10.79M 10-Q · filed 2025-08-07 | $20.76M 10-Q · filed 2025-08-07 | $26.06M derived: sum of 3 quarters · filed 2026-02-27 | $41.41M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $9.96M 10-Q · filed 2025-05-07 | $15.27M derived: sum of 2 quarters · filed 2026-02-27 | $30.62M derived: sum of 3 quarters · filed 2026-02-27 | $48.39M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $20.66M derived: sum of 2 quarters · filed 2026-02-27 | $38.42M derived: sum of 3 quarters · filed 2026-02-27 | $35.27M 10-K · filed 2026-02-27 |
| 2023-09-30 | $15.35M 10-Q · filed 2024-11-12 | $33.12M derived: sum of 2 quarters · filed 2024-11-12 | $29.97M 10-Q · filed 2024-11-12 | $28.44M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $17.77M 10-Q · filed 2024-08-09 | $14.62M 10-Q · filed 2024-08-09 | $13.09M derived: sum of 3 quarters · filed 2025-02-28 | $13.39M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$3.15M 10-Q · filed 2024-05-08 | -$4.68M derived: sum of 2 quarters · filed 2025-02-28 | -$4.38M derived: sum of 3 quarters · filed 2025-02-28 | -$123.65M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$1.23M derived: sum of 2 quarters · filed 2025-02-28 | -$120.50M derived: sum of 3 quarters · filed 2025-02-28 | -$125.24M 10-K · filed 2025-02-28 |
| 2022-09-30 | $299.00K 10-Q · filed 2023-11-09 | -$118.97M derived: sum of 2 quarters · filed 2023-11-09 | -$123.72M 10-Q · filed 2023-11-09 | -$137.80M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$119.27M 10-Q · filed 2023-08-08 | -$124.02M 10-Q · filed 2023-08-08 | -$138.10M derived: sum of 3 quarters · filed 2024-03-14 | -$139.95M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$4.74M 10-Q · filed 2023-05-09 | -$18.82M derived: sum of 2 quarters · filed 2024-03-14 | -$20.68M derived: sum of 3 quarters · filed 2024-03-14 | -$3.04M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$14.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$15.94M derived: sum of 2 quarters · filed 2024-03-14 | $1.71M derived: sum of 3 quarters · filed 2024-03-14 | $9.55M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$1.85M 10-Q · filed 2022-11-07 | $15.79M derived: sum of 2 quarters · filed 2022-11-07 | $23.63M 10-Q · filed 2022-11-07 | $19.70M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $17.64M 10-Q · filed 2022-08-08 | $25.48M 10-Q · filed 2022-08-08 | $21.56M derived: sum of 3 quarters · filed 2023-03-03 | $8.50M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $7.84M 10-Q · filed 2022-05-06 | $3.91M derived: sum of 2 quarters · filed 2023-03-03 | -$9.14M derived: sum of 3 quarters · filed 2023-03-03 | -$21.09M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | -$3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$16.98M derived: sum of 2 quarters · filed 2023-03-03 | -$28.93M derived: sum of 3 quarters · filed 2023-03-03 | -$22.48M 10-K · filed 2023-03-03 |
| 2020-09-30 | -$13.06M 10-Q · filed 2021-11-08 | -$25.01M derived: sum of 2 quarters · filed 2021-11-08 | -$18.56M 10-Q · filed 2021-11-08 | -$51.33M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$11.95M 10-Q · filed 2021-08-09 | -$5.50M 10-Q · filed 2021-08-09 | -$38.27M derived: sum of 3 quarters · filed 2022-03-01 | -$136.66M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $6.45M 10-Q · filed 2021-05-07 | -$26.32M derived: sum of 2 quarters · filed 2022-03-01 | -$124.71M derived: sum of 3 quarters · filed 2022-03-01 | -$158.34M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$32.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$131.16M derived: sum of 2 quarters · filed 2022-03-01 | -$164.78M derived: sum of 3 quarters · filed 2022-03-01 | -$241.66M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$98.39M 10-Q · filed 2020-11-06 | -$132.01M derived: sum of 2 quarters · filed 2020-11-06 | -$208.88M 10-Q · filed 2020-11-06 | -$220.44M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$33.62M 10-Q · filed 2020-08-06 | -$110.50M 10-Q · filed 2020-08-06 | -$122.06M derived: sum of 3 quarters · filed 2021-03-01 | -$111.48M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$76.87M 10-Q · filed 2020-05-11 | -$88.43M derived: sum of 2 quarters · filed 2021-03-01 | -$77.86M derived: sum of 3 quarters · filed 2021-03-01 | -$109.74M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$11.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$985.00K derived: sum of 2 quarters · filed 2021-03-01 | -$32.87M derived: sum of 3 quarters · filed 2021-03-01 | -$32.75M 10-K · filed 2021-03-01 |
| 2018-09-30 | $10.58M 10-Q · filed 2019-11-07 | -$21.31M derived: sum of 2 quarters · filed 2019-11-07 | -$21.19M 10-Q · filed 2019-11-07 | -$20.57M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$31.89M 10-Q · filed 2019-08-05 | -$31.77M 10-Q · filed 2019-08-05 | -$31.14M derived: sum of 3 quarters · filed 2020-03-02 | -$30.80M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $117.00K 10-Q · filed 2019-05-09 | $742.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.08M derived: sum of 3 quarters · filed 2020-03-02 | $1.39M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $625.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $967.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.27M derived: sum of 3 quarters · filed 2020-03-02 | $1.68M 10-K · filed 2020-03-02 |
| 2017-09-30 | $342.00K 10-Q · filed 2018-11-07 | $644.00K derived: sum of 2 quarters · filed 2018-11-07 | $1.05M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $302.00K 10-Q · filed 2018-08-09 | $710.00K 10-Q · filed 2018-08-09 | ||
| 2016-12-31 | $2.05M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |